Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Antibodies Ig G as an indicator of the dynamics of recurrent ophthalmoherpes

Poster Details

First Author: T. Valkovich BELARUS

Co Author(s):                        

Abstract Details

Purpose:

To determine the role of antibodies titer Ig G in assessing the dynamics of inflammation in recurrent ophthalmoherpes.

Setting:

Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus

Methods:

The study involved 59 patients with recurrent ophthalmoherpes: 33 - viral keratitis, 26 - keratouveitis. ELISA of blood was performed in all patients at the initial examination, at 1 and 6 months after treatment to determine of antibodies IgA, IgG, IgM for herpes virus infection 1, 2 and 5 types. Statistical data processing was carried out in accordance with the requirements for medical research.

Results:

ELISA has identified excess of antibodies titer Ig G to type 5 in 58 patients in 92 times (Me) (min-max = 0,0-1544,6 times) whereas to type 1 significantly less (Me=9). Antibody titers Ig G to type 2 were not exceed the level of standards in most cases. We were performed courses of antiviral treatment in preventive doses in cases increase of antibodies titer IgG to herpes virus infection 1, 2 and 5 types in dynamics. Recurrence of disease was observed in 9 cases (15.2%) after treatment for 6 months follow-up. At follow-up (1 year) recurrences were observed only in 3 cases (3%).

Conclusions:

Increase of antibodies titer Ig G to herpes virus 1, 2 and 5 types under normal rates Ig M and presence of chronic and recurrent inflammation is an indication for systemic antiviral treatment. Increase of antibodies titer Ig G after treatment demands carrying out additional antiviral treatment in prophylactic doses.

Financial Disclosure:

NONE

Back to Poster listing